Structure of Cabozantinib
CAS No.: 849217-68-1
*Storage:
*Shipping:
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035 and 1.3 nM, respectively. It also strongly inhibits KIT, RET, AXL, TIE2, and FLT3, with IC50 values of 4.6, 5.2, 7, 14.3, and 11.3 nM, respectively. Cabozantinib shows antiangiogenic activity, disrupts tumor vasculature, and promotes tumor and endothelial cell apoptosis.
Synonyms: XL184; BMS-907351
4.5
*For Research Use Only !
Change View
Size | Price | US Stock | Global Stock | In Stock |
1mg | łÇʶÊÊ | Inquiry | Inquiry | |
5mg | łÇ˶ÊÊ | Inquiry | Inquiry | |
10mg | łÇÿ¶ÊÊ | Inquiry | Inquiry | |
50mg | łÇó¶ÊÊ | Inquiry | Inquiry | |
100mg | łË˶ÊÊ | Inquiry | Inquiry | |
250mg | ł§Í¶ÊÊ | Inquiry | Inquiry | |
1g | łòÿ¶ÊÊ | Inquiry | Inquiry | |
5g | łËÇʶÊÊ | Inquiry | Inquiry | |
10g | ł§óʶÊÊ | Inquiry | Inquiry |
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
łÇʶÊÊ
łÇ˶ÊÊ
łÇÿ¶ÊÊ
łÇó¶ÊÊ
łË˶ÊÊ
ł§Í¶ÊÊ
łòÿ¶ÊÊ
łËÇʶÊÊ
ł§óʶÊÊ
In Stock
- +
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Marlhoux, Léna ; Arnaud, Alexandre ; Hervieu, Céline ; Makulyte, Gabriela ; Martinasso, Charlotte ; Mularoni, Angélique , et al.
Abstract: Casein kinase 2 (CK2) has emerged as a promising therapeutic target across a broad spectrum of malignancies, including pediatric and orphan cancers. The identification of a ligandable allosteric αD pocket on the CK2α subunit has enabled the development of bivalent inhibitors, which bind simultaneously to both the adenosine triphosphate (ATP) site and the allosteric pocket. Here, we report the discovery and pharmacological characterization of KDX1381, a structure-guided bivalent CK2α inhibitor with low-nanomolar potency and high selectivity, confirmed by cocrystal structures. In mice, KDX1381 suppressed CK2-driven tumor growth as a monotherapy and enhanced therapeutic efficacy when combined with vascular endothelial growth factor receptor (VEGFR) inhibitors or DNA-damaging agents in hepatocellular carcinoma and glioma models. These findings support bivalent CK2α inhibition as a differentiated therapeutic strategy with broad applicability in CK2-dependent cancers.
Show More >
Purchased from AmBeed: 61825-94-3 ; 1009820-21-6 ; 444731-52-6 ; 85622-93-1 ; 557795-19-4 ; 755037-03-7 ; 849217-68-1 ; 15663-27-1 ; 284461-73-0 ; 417716-92-8 ; 51-21-8
Show More >
CAS No. : | 849217-68-1 |
Formula : | C28H24FN3O5 |
M.W : | 501.51 |
SMILES Code : | O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC=C(OC4=CC=NC5=CC(OC)=C(OC)C=C45)C=C3 |
Synonyms : |
XL184; BMS-907351
|
MDL No. : | MFCD20926324 |
InChI Key : | ONIQOQHATWINJY-UHFFFAOYSA-N |
Pubchem ID : | 25102847 |
GHS Pictogram: | ![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H320-H335 |
Precautionary Statements: | P261-P280-P301+P312-P302+P352-P305+P351+P338 |
Target |
|
In Vitro:
Cell Line
| Concentration | Treated Time | Description | References |
HCT116 cells | 5 μM | 24 h | To evaluate the effect of Cabozantinib on autophagy, results showed that Cabozantinib significantly induced autophagy. | PMC6168336 |
HT29 cells | 5 μM | 24 h | To evaluate the effect of Cabozantinib on autophagy, results showed that Cabozantinib significantly induced autophagy. | PMC6168336 |
2H11 cells | 1 μM | 20 h | To evaluate the effect of Cabozantinib on tube formation in 2H11 cells, results showed that Cabozantinib inhibited tube formation. | PMC9444986 |
H460/MX20 | 5 μM | 72 h | Cabozantinib significantly sensitized H460/MX20 cells to ABCG2 substrate drugs (such as mitoxantrone, SN-38, and topotecan), reversing ABCG2-mediated multidrug resistance. | PMC5392419 |
ABCG2-482-R2 | 5 μM | 72 h | Cabozantinib significantly sensitized ABCG2-482-R2 cells to ABCG2 substrate drugs (such as mitoxantrone, SN-38, and topotecan), reversing ABCG2-mediated multidrug resistance. | PMC5392419 |
ABCG2-482-G2 | 5 μM | 72 h | Cabozantinib significantly sensitized ABCG2-482-G2 cells to ABCG2 substrate drugs (such as mitoxantrone, SN-38, and topotecan), reversing ABCG2-mediated multidrug resistance. | PMC5392419 |
ABCG2-482-T7 | 5 μM | 72 h | Cabozantinib significantly sensitized ABCG2-482-T7 cells to ABCG2 substrate drugs (such as mitoxantrone, SN-38, and topotecan), reversing ABCG2-mediated multidrug resistance. | PMC5392419 |
JHH5 cells | 3 µM | 72 h | To evaluate the inhibitory effect of Cabozantinib on JHH5 cells, results showed that Cabozantinib alone only partially interfered with cell viability | PMC9700715 |
Hep3B cells | 3 µM | 72 h | To evaluate the inhibitory effect of Cabozantinib on Hep3B cells, results showed that Cabozantinib alone only partially interfered with cell viability | PMC9700715 |
Huh7 cells | 3 µM | 72 h | To evaluate the inhibitory effect of Cabozantinib on Huh7 cells, results showed that Cabozantinib alone only partially interfered with cell viability | PMC9700715 |
SC1 cells | 10 μM | 24 h | To detect the release of CXCL12 after Cabozantinib treatment, the results showed that Cabozantinib treatment significantly increased the release of CXCL12. | PMC5501767 |
SC1 cells | 10 μM | 28 h | To detect the release of HMGB1 after Cabozantinib treatment, the results showed that Cabozantinib treatment significantly increased the release of HMGB1. | PMC5501767 |
HCT116 cells | 5 μM | 24 h | To evaluate the effect of Cabozantinib on autophagy, results showed that Cabozantinib significantly induced autophagy | PMC6168336 |
HT29 cells | 5 μM | 24 h | To evaluate the effect of Cabozantinib on autophagy, results showed that Cabozantinib significantly induced autophagy | PMC6168336 |
In Vivo:
Species
| Animal Model
| Administration | Dosage | Frequency | Description | References |
NOD/SCID mice | Peritoneal dissemination model | Intraperitoneal injection | 30 mg/kg | 5 times per week for 15 days | To evaluate the antitumor efficacy of cabozantinib as monotherapy or in combination with nal-IRI in gastric cancer mouse models. Results showed that cabozantinib monotherapy significantly extended animal survival (24 days, a 33% increase), and its combination with nal-IRI further extended survival (50 days, a 178% increase). | PMC9377761 |
Nude mice | Colorectal cancer patient-derived xenograft model | Oral | 30 mg/kg | Daily for 28 days | To evaluate the antitumor effects of Cabozantinib in colorectal cancer xenograft models, results showed that Cabozantinib significantly inhibited tumor growth. | PMC6168336 |
mice | ccRCC tumor xenograft model | oral gavage | 10mg/kg | daily | Cabozantinib significantly reduced the tumor growth of the ccRCC M62 tumor xenografts. | PMC7015045 |
mice | PTEN/p53 deficient prostate cancer model | oral | 100 mg/kg | once daily for 3 weeks | Cabozantinib significantly reduced tumor volume and nearly completely cleared poorly differentiated prostate cancer within 4 days. | PMC5501767 |
Mice | Colorectal cancer patient-derived xenograft model | Oral | 30 mg/kg | Once daily for 28 days | To evaluate the antitumor effects of Cabozantinib in colorectal cancer xenograft models, results showed that Cabozantinib significantly inhibited tumor growth and reduced tumor vascularity | PMC6168336 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT05135975 | Neuroblastoma|Sarcoma | PHASE2 | RECRUITING | 2025-12-29 | Children's Hospital of Alabama... More >>/UAB, Birmingham, Alabama, 35233, United States|Children's Hospital of Colorado, Aurora, Colorado, 80045, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|Children's Hospital at Montefiore, Bronx, New York, 10467, United States|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States|Primary Children's Hospital, Salt Lake City, Utah, 84113, United States Less << |
NCT01755195 | Refractory Soft Tissue Sarcoma... More >>s Less << | PHASE2 | COMPLETED | 2023-09-11 | National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less << |
NCT06548867 | Metastatic Renal Cell Carcinom... More >>a Less << | RECRUITING | 2025-06-30 | AUSL-IRCCS of Reggio Emilia, R... More >>eggio Emilia, 42123, Italy Less << | |
NCT05425004 | Meningioma | PHASE2 | RECRUITING | 2025-05-28 | Miami Cancer Institute at Bapt... More >>ist Health, Inc., Miami, Florida, 33176, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 100653, United States|Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States Less << |
NCT05265988 | Carcinoma Prostate | PHASE2 | COMPLETED | 2024-06-29 | Alfredo Berruti, Brescia, 2512... More >>3, Italy Less << |
NCT00215605 | Lymphoma|Cancer|Thyroid Carcin... More >>oma Less << | PHASE1 | COMPLETED | 2025-07-12 | University of Chicago, Chicago... More >>, Illinois, 60637, United States|Johns Hopkins University, Baltimore, Maryland, 21231, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10021, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|Univ. of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States Less << |
NCT03911193 | Non-Small Cell Lung Cancer | PHASE2 | UNKNOWN | 2025-09-20 | A.O. "S.Giuseppe Moscati", Ave... More >>llino, AV, 83100, Italy|IRCCS Oncologico Giovanni Paolo II, Bari, BA, 70124, Italy|A.O.U. Careggi, Firenze, FI, 50134, Italy|Irccs Irst, Meldola, FO, 47014, Italy|Ospedale Infermi Rimini, Rimini, FO, 47923, Italy|A.O. Papardo, Messina, ME, 98158, Italy|Istituto Europeo di Oncologia, Milano, MI, 20141, Italy|Ospedale San Gerardo, Monza, MI, 20900, Italy|AOU Policlinico di Modena, Modena, MO, 41124, Italy|Casa di Cura La Maddalena, Palermo, PA, 90146, Italy|Istituto Oncologico Veneto, Padova, PD, 35128, Italy|A.O. S.M. Misericordia, Perugia, PG, 06129, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, PI, 56124, Italy|Azienda Ospedaliero- Universitaria di Parma, Parma, PR, 43126, Italy|AUSL Reggio Emilia- IRCCS Arcispedale S.M. Nuova, Reggio Emilia, RE, 42123, Italy|Fondazione Policlinico Gemelli, Roma, RM, 00168, Italy|Istituto Nazionale Tumori Regina Elena, Roma, RO, 00144, Italy|A.O.U. S. Luigi Gonzaga, Orbassano, Torino, 10043, Italy|AUSL della Romagna, Ravenna, Italy|Azienda Ospedaliero Universitaria Integrata di Verona, Verona, 37134, Italy Less << |
NCT04588051 | HCC | PHASE2 | ACTIVE_NOT_RECRUITING | 2027-12-31 | Department of Clinical Oncolog... More >>y, Prince of Wales Hospital, Hong Kong, Hong Kong|ASAN Medical Center, Seoul, Korea, Republic of Less << |
NCT03967522 | Metastatic Renal Cell Carcinom... More >>a Less << | PHASE2 | COMPLETED | 2024-11-01 | Institut de Cancérologie de l'... More >>Ouest-Site Paul Papin, Angers, 49005, France|CHU Besancon, Besan?on, 25030, France|CHU Bordeaux, Bordeaux, 33075, France|Centre Jean Perrin, Clermont-Ferrand, 63011, France|Centre Leon Berard, Lyon, 69373, France|Institut de Cancérologie de la Lorraine, Nancy, 54519, France|Hopital Européen Georges Pompidou, Paris, 75015, France|Institut de Cancérologie de l'Ouest-site René Gauducheau, Saint-Herblain, 44805, France|ICANS, Strasbourg, 67000, France|Hopital Foch, Suresnes, 92150, France|IUCT-Institut Claudius Regaud, Toulouse, 31059, France|Institut Gustave Roussy, Villejuif, 94805, France Less << |
NCT01428219 | Prostate Cancer Metastatic | PHASE2 | TERMINATED | 2025-09-15 | University of Michigan, Ann Ar... More >>bor, Michigan, 48109, United States Less << |
NCT03729297 | Salivary Gland Cancer | PHASE2 | TERMINATED | 2019-11-06 | Radboudumc, Nijmegen, Gelderla... More >>nd, 6500HB, Netherlands Less << |
NCT02036476 | Merkel Cell Carcinoma|Skin Can... More >>cer Less << | PHASE2 | TERMINATED | 2025-07-16 | Brigham and Women's Hospital, ... More >>Boston, Massachusetts, 02115, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less << |
NCT01738438 | Breast Cancer | PHASE2 | COMPLETED | 2025-05-15 | Dana-Farber Cancer Institute a... More >>t Faulkner Hospital, Boston, Massachusetts, 02130, United States|Massachusetts General Hospital, Boston, Massachusetts, 02214, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less << |
NCT01582295 | Multiple Myeloma | PHASE1 | COMPLETED | 2025-11-14 | Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less << |
NCT04497038 | Advanced Adult Hepatocellular ... More >>Carcinoma Less << | PHASE1|PHASE2 | TERMINATED | 2023-05-02 | Northwestern University, Chica... More >>go, Illinois, 60611, United States|University of Chicago, Chicago, Illinois, 60637, United States|University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, 48109, United States|University of Texas Southwestern Medical Center, Dallas, Texas, 75390, United States Less << |
NCT04066595 | Urothelial Carcinoma | PHASE2 | TERMINATED | 2021-07-01 | Department of Urology of the U... More >>niversity Medical Center Mainz, Mainz, 55131, Germany Less << |
NCT04631744 | Prostate Cancer | PHASE2 | RECRUITING | 2025-07-27 | Karmanos Cancer Institute, Det... More >>roit, Michigan, 48201, United States|Columbia University Irving Medical Center, New York, New York, 10032, United States|Weill Cornell Medicine, New York, New York, 10065, United States|University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, 15232, United States Less << |
NCT06535737 | Hepatocellular Carcinoma Non-r... More >>esectable Less << | PHASE2 | NOT_YET_RECRUITING | 2025-12-26 | - |
NCT01068782 | Astrocytic Tumors | PHASE2 | COMPLETED | 2025-10-13 | Birmingham, Alabama, 35294, Un... More >>ited States|Encinitas, California, 92024, United States|Pleasant Hill, California, 94523, United States|Chicago, Illinois, 60611, United States|Chicago, Illinois, 60637, United States|Boston, Massachusetts, 02115, United States|Detroit, Michigan, 48202, United States|Minneapolis, Minnesota, 55407, United States|Amhearst, New York, 14226, United States|Rochester, New York, 14642, United States|Cleveland, Ohio, 44195, United States|Hershey, Pennsylvania, 17033, United States|Dallas, Texas, 75246, United States|Dallas, Texas, 75426, United States|San Antonio, Texas, 78229, United States|Charlottesville, Virginia, 22908, United States|Seattle, Washington, 98122, United States|Calgary, Alberta, Canada|Montreal, Quebec, Canada Less << |
NCT03586973 | Advanced Hepatocellular Carcin... More >>oma Less << | PHASE2 | COMPLETED | 2021-06-29 | Aichi Cancer Center Hospital, ... More >>Nagoya, Aichi, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, Japan|Iizuka Hospital, Iizuka, Fukuoka, Japan|Kurume University Hospital, Kurume, Fukuoka, Japan|Sapporo-Kosei General Hospital, Sapporo, Hokkaido, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Musashino Hospital, Musashino, Tokyo, Japan|Chiba University Hospital, Chiba, Japan|Hiroshima University Hospital, Hiroshima, Japan|Okayama University Hospital, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan Less << |
NCT03943602 | Penile Squamous Cell Carcinoma | PHASE2 | UNKNOWN | 2022-09-01 | Fondazione IRCCS Istituto Nazi... More >>onale dei Tumori, Milano, 20133, Italy Less << |
NCT00704288 | Glioblastoma Multiforme | PHASE2 | COMPLETED | 2025-12-12 | University of California, Los ... More >>Angeles, Los Angeles, California, 90095, United States|University of California, San Francisco, San Francisco, California, 94143, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02115, United States|Henry Ford Health System, Detroit, Michigan, 48202, United States|Duke University, The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, 27710, United States|University of Texas M.D. Anderson Cancer Center, Houston, Texas, 77030, United States|University of Virginia Health System, Charlottesville, Virginia, 22908, United States|University of Washington, Seattle, Washington, 98195, United States Less << |
NCT04205799 | Advanced/Metastatic Cervical C... More >>ancer Less << | PHASE2 | COMPLETED | 2023-01-15 | Institut de cancérologie de l'... More >>Ouest, Angers, France|Centre Fran?ois Baclesse, Caen, France|Centre Oscar LAMBRET, Lille, France|Centre Léon Bérard, Lyon, France|Institut de Cancérologie de Montpellier, Montpellier, France|Institut de cancérologie de l'Ouest, Nantes, France|Institut CURIE, Saint-Cloud, France|Institut Gustave Roussy, Villejuif, France Less << |
NCT04022343 | Clear Cell Renal Cell Carcinom... More >>a|Renal Cell Carcinoma|Stage III Renal Cell Cancer AJCC v8 Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-02-02 | Emory University Hospital/Wins... More >>hip Cancer Institute, Atlanta, Georgia, 30322, United States Less << |
NCT01954745 | Bile Duct Cancer|Intrahepatic ... More >>Cholangiocarcinoma|Cholangiocarcinoma of the Extrahepatic Bile Duct Less << | PHASE2 | COMPLETED | 2025-06-16 | Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States|Brigham and Women's Hospital, Boston, Massachusetts, 02215, United States|Dana Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less << |
NCT04416646 | Renal Cell Carcinoma | ACTIVE_NOT_RECRUITING | 2024-03-01 | Istituto Oncologico Veneto, Pa... More >>dova, 35100, Italy Less << | |
NCT02101736 | NF1|Neurofibromatosis|Plexifor... More >>m Neurofibromas Less << | PHASE2 | COMPLETED | 2022-02-16 | Children's Hospital Los Angele... More >>s, Los Angeles, California, 90027, United States|Children's National Medical Center, Washington, District of Columbia, 20010, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|University of Chicago, Chicago, Illinois, 60637, United States|Indiana Unversity, Indianapolis, Indiana, 46202, United States|National Cancer Institute (NCI), Bethesda, Maryland, 20892, United States|Children' Hospital Boston and Massachusetts General Hospital, Boston, Massachusetts, 02115, United States|Washington University - St. Louis, Saint Louis, Missouri, 63110, United States|New York University Medical Center, New York, New York, 10016, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19096, United States|University of Utah, Salt Lake City, Utah, 84132, United States Less << |
NCT02885324 | Glioblastoma Multiforme|Anapla... More >>stic Astrocytoma|Malignant Brain Tumor|High Grade Glioma Less << | PHASE2 | TERMINATED | 2020-08-25 | Riley Hospital for Children at... More >> IU Health, Indianapolis, Indiana, 46202, United States Less << |
NCT04510688 | Renal Cell Carcinoma | COMPLETED | 2022-06-30 | Hospital Universitario Reina S... More >>ofía, Córdoba, Andalucía, 14004, Spain|Hospital Universitario Juan Ramón Jiménez, Huelva, Andalucía, 21005, Spain|Complejo Hospitalario de Jaén, Jaén, Andalucía, 23007, Spain|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33011, Spain|Hospital Universitari Parc Taulí, Sabadell, Barcelona, 08208, Spain|Hospital Universitario de León, León, Castilla Y León, 24008, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, 08041, Spain|Hospital Universitari Sant Joan de Reus, Reus, Catalunya, 43204, Spain|Consorci Corporació Sanitària Parc Taulí de Sabadell, Sabadell, Catalunya, 08208, Spain|Hospital Universitari i Politècnic La Fe, Valencia, Comunidad Valenciana, 46026, Spain|Hospital Clínico Universitario de Valenica, Valencia, Comunitat Valenciana, 46010, Spain|Hospital Universitari Dr. Peset, Valencia, Comunitat Valenciana, 46017, Spain|Hospital Universitario de Badajoz, Badajoz, Extremadura, 06080, Spain|Centro Oncológico de Galicia, A Coru?a, Galicia, 15009, Spain|Complejo Hospitalario Universitario de Ferrol, Ferrol, Galicia, 15405, Spain|Complejo Hospitalario Universitario Ourense, Ourense, Galicia, 32005, Spain|Hospital Universitari Son Espases, Palma De Mallorca, Illes Ballears, 07120, Spain|Hospital Son Llatzer, Palma De Mallorca, Islas Baleares, 07198, Spain|Hospital Unviersitario de Gran Canaria Doctor Negrin, Las Palmas De Gran Canaria, Islas Canarias, 35010, Spain|Hospital Universitario Nuestra Se?ora de Candelaria, Santa Cruz De Tenerife, Islas Canarias, 38010, Spain|Hospital Del Mar, Barcelona, 08003, Spain|Hospital Universitari Vall D'Hebron, Barcelona, 08035, Spain|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario de Burgos, Burgos, 09006, Spain|Hospital Provincial de Castellón, Castellón De La Plana, 12002, Spain|Hospital General de Ciudad Real, Ciudad Real, 13005, Spain|Hospital San Pedro de Alcántara, Cáceres, 10003, Spain|Hospital Universitario Lucus Augusti, Lugo, 27003, Spain|Hospital Virgen de La Salud, Toledo, 45004, Spain|Fundación Instituto Valenciano de Oncología, Valencia, 46009, Spain|Hospital Arnau de Vilanova, Valencia, 46015, Spain|Hospital Universitario Alvaro Cunqueiro, Vigo, 36312, Spain Less << | |
NCT06171854 | Refractory Colorectal Adenocar... More >>cinoma Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2024-12-31 | A.O.U dell'Università degli St... More >>udi della Campania "Luigi Vanvitelli", Napoli, Italy Less << |
NCT04876456 | Germ Cell Tumor|Seminoma|Non-s... More >>eminomatous Germ Cell Tumor|Ovarian Germ Cell Tumor Less << | PHASE2 | RECRUITING | 2025-02-26 | Indiana University Melvin & Br... More >>en Simon Cancer Center, Indianapolis, Indiana, 46202, United States Less << |
NCT06156410 | Ewing Sarcoma|Osteosarcoma | PHASE1 | RECRUITING | 2025-11-28 | University of California San F... More >>rancisco, San Francisco, California, 94143, United States|Children's Hospital Colorado, Aurora, Colorado, 80045, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States Less << |
NCT04316182 | Hepatocellular Carcinoma | PHASE2 | COMPLETED | 2023-02-22 | Hospital Clinic, Barcelona, Sp... More >>ain|Hospital Vall d'Hebron, Barcelona, Spain|Institut Català D'Oncologia - Hospital Duran I Reynals, Barcelona, Spain|Hospital Puerta de Hierro, Madrid, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital Central de Asturias, Oviedo, Spain Less << |
NCT04511455 | Hepatocellular Carcinoma Non-r... More >>esectable|Metastatic Hepatocellular Carcinoma Less << | PHASE2 | COMPLETED | 2024-12-31 | Helios Klinikum Bad Saarow, Ba... More >>d Saarow, 15526, Germany|Universit?tsklinikum Halle (Saale), Halle, 06120, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universit?tsklinikum Schleswig-Holstein, Kiel, 24105, Germany|Universit?tsklinikum K?ln, K?ln, 50937, Germany|VK&K Studien, Landshut, 84036, Germany|Universit?tsklinikum Schleswig-Holstein, Lübeck, 23538, Germany|Klinikum rechts der Isar der Technischen Universit?t München, München, 81675, Germany|Johanna Etienne Krankenhaus, Neuss, 41462, Germany|Universit?tsklinikum Ulm, Ulm, 89081, Germany Less << |
NCT05660954 | Differentiated Thyroid Cancer | PHASE2 | ACTIVE_NOT_RECRUITING | 2025-06-25 | Hospital Universitario Central... More >> de Asturias, Oviedo, Asturias, 33011, Spain|Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, 28933, Spain|Complexo Hospitalario Universitario A Coru?a, A Coru?a, 15006, Spain|Hospital Universitario Vall d'Hebron, Barcelona, 08035, Spain|Hospital Clínic de Barcelona, Barcelona, 08036, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Hospital Clínico San Carlos, Madrid, 28040, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Hospital General Universitario Morales Meseguer, Murcia, 30008, Spain|Complejo Asistencial Universitario de Salamanca, Salamanca, 37007, Spain Less << |
NCT03945773 | Locally Advanced or Metastatic... More >> Renal Cell Carcinoma Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2099-09-30 | SALK - Salzburger Landesklinik... More >>, Salzburg, A-5020, Austria|CHRU Besan?on, Besan?on, 25000, France|Centre Jean Perrin, Clermont-Ferrand, 63011, France|Centre Léon Bérard, Lyon, 69008, France|Institut Paoli Calmettes, Marseille, 13009, France|Institut de Cancérologie de Lorraine, Nancy, 54511, France|CHU de N?mes - Institut de Cancérologie du Gard, N?mes, 30029, France|Institut Mutualiste Montsouris, Paris, 75014, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, 69495, France|Institut de Cancérologie de l'Ouest, Saint-Herblain, 44800, France|CHU Strasbourg, Strasbourg, 67091, France|Institut Claudius Régaud, Toulouse, 31059, France|Gustave Roussy, Villejuif, 94805, France|Universit?tsmedzin Charité, Berlin, D-10117, Germany|University Hospital Carl Gustav Carus Dresden, Dresden, D-1307, Germany|Universit?tsklinikum Essen, Essen, D-45147, Germany|University Cancer Center Hamburg Eppendorf, Hamburg, d-20246, Germany|Medizinische Hochschule Hannover, Hannover, D-30625, Germany|Klinikum Der Friedrich-Schiller-Universitaet Jena, Jena, D-07747, Germany|Universit?tsklinikum Schleswig-Holstein, Lübeck, D-23538, Germany|Otto-von-Guericke-Universit?t University hospital Magdeburg, Magdeburg, D-39120, Germany|University, Hospital Münster, Münster, D-48149, Germany|Caritas Krankenhaus St.Josef Klinik für Urologie, Regensburg, D-93053, Germany|University Hospital Tuebingen, Tübingen, D-72076, Germany|The Netherlands Cancer Institute - Oncology, Amsterdam, 1066 CX, Netherlands|Maxima Medisch Centrum, Eindhoven, 5604 DB, Netherlands|Leiden University Medical Center, Leiden, 2300-RC, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, 3584 CX, Netherlands|Hospital de La Santa Creu i Sant Pau, Barcelona, 08041, Spain|Hospital Lucus Augusti, Lugo, 27003, Spain|M.D. Anderson Center Madrid, Madrid, 28033, Spain|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain|Universit?tsspital Bern, Inselspital, Bern, 3010, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, 1011, Switzerland|Kantonsspital St. Gallen, Saint Gallen, 9007, Switzerland|Western General Hospital - Edinburgh Cancer Centre, Edinburgh, EH4 2XU, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|The Christie NHS Foundation Trust, Manchester, M20 4BX, United Kingdom|Mount Vernon Hospital, Northwood, HA6 2RN, United Kingdom|Royal Cornwall Hospital (RCH) - Sunrise Centre, Truro, TR1 3LJ, United Kingdom Less << |
NCT04454762 | Hepatocellular Carcinoma | PHASE2 | UNKNOWN | 2024-02-01 | Department of Internal Medicin... More >>e I, Johannes Gutenberg University Mainz, Mainz, 55131, Germany Less << |
NCT03685448 | Renal Cell Carcinoma|Papillary... More >> Renal Cell Carcinoma Type 1|Papillary Renal Cell Carcinoma Type 2|Chromophobe Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Xp11.2 Translocation-Related Renal Cell Carcinoma Less << | PHASE2 | UNKNOWN | 2024-04-30 | Border Medical Oncology Resear... More >>ch Unit / The Border Cancer Hospital, Albury, New South Wales, 2460, Australia|Campbelltown Hospital, Campbelltown, New South Wales, 2560, Australia|St George Hospital, Kogarah, New South Wales, Australia|Macquarie University Hospital, Macquarie Park, New South Wales, 2109, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, 5042, Australia|Adelaide Cancer Centre / Ashford Cancer Centre Research / Cancer Care SA, Kurralta Park, South Australia, 5037, Australia|Box Hill Hospital - Eastern Health, Box Hill, Victoria, 3128, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Goulburn Valley Health, as a satellite site under the supervision of Border Medical Oncology Research Unit, via the Tele-trial model, Shepparton, Victoria, 3630, Australia Less << |
NCT02041260 | Differentiated Thyroid Cancer ... More >>(DTC)|Poorly Differentiated Thyroid Cancer Less << | PHASE2 | UNKNOWN | 2025-05-22 | Abramson Cancer Center of the ... More >>University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States Less << |
NCT04767906 | Hepatocellular Carcinoma | PHASE2 | COMPLETED | 2024-07-19 | Technische Universit?t Dresden... More >>, Medizinische Fakult?t Carl Gustav Carus Medizinische Klinik und Poliklinik I, Dresden, Saxonia, 01307, Germany|MVZ Mitte/MVZ Delitzsch GmbH, Leipzig, Saxonia, 04103, Germany|University Hospital Leipzig, Leipzig, Saxonia, 04103, Germany|Charite Universit?tsmedizin, Campus Virchow Klinikum, Klinik für Hepatologie/Gastroenterologie, Berlin, 13353, Germany|Universit?tsklinikum Mannheim, Mannheim, 68167, Germany Less << |
NCT01688999 | Urothelial Carcinoma|Urethral ... More >>Neoplasms|Urinary Bladder Neoplasms|Kidney Neoplasms Less << | PHASE2 | COMPLETED | 2020-09-14 | National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less << |
NCT04524208 | Neuroendocrine Tumors|Neuroend... More >>ocrine Carcinoma Less << | PHASE2 | ACTIVE_NOT_RECRUITING | 2024-10-31 | Medizinische Universit?t Wien,... More >> Wien, Austria|University Medical Center G?ttingen, G?ttingen, Lower Saxony, 37075, Germany|Zentralklinik Bad Berka GmbH, Bad Berka, 99437, Germany|Universit?tsklinikum Carl Gustav Carus, Dresden, 01307, Germany|Universit?tsklinikum Erlangen, Erlangen, Germany|Universit?tsklinikum Freiburg, Freiburg, 79106, Germany|Universit?tsklinikum Halle, Halle, Germany|Asklepios St. Georg, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Klinikum Heidelberg, Heidelberg, Germany|Universit?tsmedizin Mannheim, Mannheim, Germany|Universit?tsklinikum Gie?en und Marburg GmbH, Marburg, 35043, Germany|Johannes-Wesling-Klinikum Minden, Minden, Germany|Klinikum Ulm, Ulm, Germany|Universit?tsklinik Würzburg, Würzburg, Germany Less << |
NCT05613894 | Metastatic Castration-resistan... More >>t Prostate Cancer Less << | PHASE1 | RECRUITING | 2028-05-01 | Huntsman Cancer Institute at U... More >>niversity of Utah, Salt Lake City, Utah, 84112, United States Less << |
NCT01639508 | Non-Small Cell Lung Cancer | PHASE2 | RECRUITING | 2025-07-26 | Memorial Sloan Kettering Baski... More >>ng Ridge, Basking Ridge, New Jersey, 07920, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, 07748, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, 07645, United States|Memorial Sloan Kettering Commack, Commack, New York, 11725, United States|Memorial Sloan Kettering Westchester, Harrison, New York, 10604, United States|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States|Memorial Sloan Kettering Nassau, Uniondale, New York, 11553, United States Less << |
NCT05100082 | Hepatocellular Cancer | ACTIVE_NOT_RECRUITING | 2025-11-30 | Takeda Selected Site, Tokyo, J... More >>apan Less << | |
NCT04134390 | Old Age; Debility|Renal Carcin... More >>oma Metastatic Less << | PHASE2 | COMPLETED | 2023-11-22 | Hospital de Ciudad Real, Ciuda... More >>d Real, Spain|ICO L'Hospitalet, L'Hospitalet De Llobregat, Spain|Hospital Insular de Gran Canarias, Las Palmas De Gran Canaria, Spain|Hospital Lucus Augusti, Lugo, Spain|Hospital Infanta Sofia, Madrid, Spain|Hospital Universitario de Donostia, San Sebastián, Spain|Fundación Instituto Valenciano de Oncologia, Valencia, 46009, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital Universitario La Fe, Valencia, Spain|Hospital Clinico de Valladolid, Valladolid, Spain Less << |
NCT04204850 | Hepatocellular Carcinoma|Recur... More >>rent Cancer|Liver Transplant Less << | PHASE2 | RECRUITING | 2025-12-07 | Princess Margaret Cancer Centr... More >>e, Toronto, Ontario, M5G 2M9, Canada Less << |
NCT01588821 | Lung Cancer|Solid Tumor (Not B... More >>reast or Prostate Cancers) Less << | PHASE2 | COMPLETED | 2025-06-19 | Massachusetts General Hospital... More >>, Boston, Massachusetts, 02114, United States Less << |
NCT01834651 | Prostate Cancer | PHASE2 | COMPLETED | 2016-07-18 | Cedars-Sinai Medical Center, L... More >>os Angeles, California, 90048, United States Less << |
NCT03339219 | Advanced Renal Cell Carcinoma | PHASE2 | COMPLETED | 2020-08-25 | Nagoya University Hospital, Na... More >>goya, Aichi, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Sapporo Medical University Hospital, Sapporo, Hokkaido, Japan|Kobe University Hospital, Kobe, Hyogo, Japan|Yokohama City University Hospital, Yokohama, Kanagawa, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Nippon Medcal School Hospital, Bunkyo-ku, Tokyo, Japan|Toranomon Hospital, Minato-ku, Tokyo, Japan|Keio University Hospital, Shinjuku-ku, Tokyo, Japan|Tokyo Women's Medical University Hospital, Shinjuku-ku, Tokyo, Japan|Kyushu University Hospital, Fukuoka, Japan|Niigata University Medical and Dental Hospital, Niigata, Japan|Okayama University Hospital, Okayama, Japan|Osaka City University Hospital, Osaka, Japan|Osaka International Cancer Institute, Osaka, Japan|Tokushima University Hospital, Tokushima, Japan|Yamagata University Hospital, Yamagata, Japan Less << |
NCT03201250 | Multiple Myeloma|Refractory Mu... More >>ltiple Myeloma|Relapsed/Refractory Multiple Myeloma Less << | PHASE1|PHASE2 | TERMINATED | 2021-04-12 | University of Nebraska Medical... More >> Center, Omaha, Nebraska, 68198, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, 77030, United States Less << |
NCT04804813 | Renal Cell Carcinoma | COMPLETED | 2024-03-31 | Takeda Selected Site, Tokyo, J... More >>apan Less << | |
NCT06377722 | Renal Cell Carcinoma Metastati... More >>c|Renal Cell Carcinoma Stage IV|Renal Cell Carcinoma Stage III Less << | PHASE2 | TERMINATED | 2022-08-09 | Hospital Universitario Central... More >> de Asturias, Oviedo, Asturias, Spain|Institut Català d'Oncologia. Idibell, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario de Valdecilla, Santander, Cantabria, Spain|Hospital Univeristario 12 de Octubre, Madrid, 28041, Spain|Centro Oncológico Clara Campal - HM CIOCC, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Hospital Universitario Severo Ochoa, Madrid, Spain Less << |
NCT01703065 | Adenocarcinoma of the Prostate... More >>|Castration-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage III Prostate Cancer|Stage IV Prostate Cancer Less << | PHASE2 | TERMINATED | 2015-09-18 | Seattle Cancer Care Alliance/U... More >>niversity of Washington, Seattle, Washington, 98109, United States Less << |
NCT01466036 | Carcinoid Tumor|Pancreatic Neu... More >>roendocrine Tumor Less << | PHASE2 | COMPLETED | 2025-12-23 | Massachusetts General Hospital... More >>, Boston, Massachusetts, 02214, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 1.99mL 0.40mL 0.20mL | 9.97mL 1.99mL 1.00mL | 19.94mL 3.99mL 1.99mL |
Tags: Cabozantinib | XL184 | BMS-907351 | XL 184 | XL-184 | BMS907351 | BMS 907351 | BMS-907351 | VEGFR | c-Met | multi-targeted tyrosine kinase inhibitor | MET | VEGFR2 | Tyro3 | Axl | Mer | RET | angiogenesis | antiangiogenic | apoptosis | Vascular endothelial growth factor receptor | 849217-68-1
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL